PubMed Health⌕ Search

Biomedical subjects

T Himori

Publications and source records attributed to T Himori.

At least 19 recordsLinked to original sources
PubMed1987

[A case of multiple myeloma responding very well to the combination of K18 with prednisolone].

A case of multiple myeloma refractory to various anticancer drugs was effectively treated with the combination of K 18 with prednisolone, which led to a remarkable decrease of serum M-protein and overall recovery. In 8 months of the treatment, although slight bone marrow suppression was noted, no severe side effect was observed. The patient has survived for more than one year in remission. We suggest that the combination of K18 with prednisolone may be effective for multiple myeloma which is unresponsive to treatment with anticancer drugs.

Drug Combinations↗
PubMed1986

[Serum copper and the copper:zinc ratio in patients with gastric cancer].

Serum copper levels, serum zinc levels, and serum Cu:Zn ratios were evaluated in 100 patients with gastric cancer. The following conclusions were drawn from the results: Serum copper levels and the serum Cu:Zn ratio were elevated, while serum zinc levels were decreased, reflecting the progress of the disease. Since serum zinc levels varied more remarkably, it was suggested that this value was more useful than serum copper levels as an indicator of tumor activity. Serum copper and zinc levels were independent of the presence of liver metastasis and of the histological types. It was shown that the serum copper levels correlated (significantly) to the survival time (p less than 0.005).

Adult↗
PubMed1985

Ultrastructural peroxidase cytochemistry of three established human myelogenous leukemia cell lines, HL-60, KG-1 and ML-2.

We studied the ultrastructural peroxidase cytochemistry of three established human acute myelogenous leukemia cell lines (HL-60, KG-1 and ML-2) to clarify the cytochemical differences and the differences in maturation/differentiation stages. HL-60 cells contained azurophil granules which exhibited strong peroxidase reaction. The more central region of individual granules is less reactive than the outer portion of these granules. The secretory apparatus of HL-60 cells, i.e. rough endoplasmic reticulum, perinuclear cisterna and Golgi apparatus, also contained peroxidase-reactive material. ML-2 cells contained azurophil granules with peroxidase reaction; however, nuclear membranes were peroxidase-negative and thin cisternae of rough endoplasmic reticulum exhibited only a faint peroxidase reaction. KG-1 cells were peroxidase-negative. From these findings KG-1 is classified as the least mature of the cell lines studied. ML-2 cells are considered early promyelocytes and HL-60 cells as late promyelocytes.

Cell Differentiation↗
PubMed1985

Imbalance of T cell subsets in cancer patients and its modification with bestatin, a small molecular immunomodifier.

The peripheral T lymphocyte subsets and natural killer (NK) cells of patients with cancer were studied by monoclonal antibody assays in comparison with those of non-cancer individuals. An imbalance of immunoregulatory T cell subsets was frequently found in the group of cancer patients (n = 26), being characterized by a relatively high proportion of OKT8+ cells (45.0 +/- 12.0%, p less than 0.01) and a low OKT4+/OKT8+ ratio (1.29 +/- 0.56, p less than 0.05). T cell level showed no significant difference as assessed by either OKT3 or rosette formation with sheep erythrocytes (E). The effect of bestatin was examined in 10 of these cancer patients. The relative proportion of T cell subsets tended to normalize 2 to 6 weeks after starting the daily doses of 30 mg per body. The mean percentage of OKT8+ cells decreased from 47.2 to 33.4 (p less than 0.01), while the helper to suppressor ratio increased from 1.18 to 1.79 (p less than 0.01). A significant increase was also found in the percentage and number of OKT4+ cells and HNK-1+ cells after the drug administration, while T cell level tended to converge to a normal range.

Adjuvants, Immunologic↗
PubMed1985

[The pace of development of approved anticancer agents in Japan].

We investigated the pace of development of 48 approved anticancer agents except for endocrine in Japan up to the end of 1984. Forty-six new anticancer agents on which phase I-II studies had been carried out in our department from 1963 to 1984 and 34 anticancer agents approved in the USA were also referred to. Forty-eight approved drugs consisted of 23 domestic and 25 imported types. It was shown that the ability to develop new anticancer agents in Japan had grown remarkably after around 1970. Fourteen new domestic anticancer agents had been approved after 1973, whereas only 8 imported ones had been approved in the same period. Although more anticancer agents were approved in Japan than in the USA, the marketing of some anticancer agents approved in Japan was discontinued because of the lack of sufficient efficacy on reevaluation study or reduced efficacy compared with newly developed anticancer agents. Anticancer agents approved in the USA had a tendency to be used all over the world and for a long period. Many new domestic anticancer agents approved recently and which are under phase studies are derivatives of fluorinated pyrimidines, cytosine arabinoside and anthracyclines. The development of new domestic anticancer agents with an entirely new mode of action is therefore desirable.

Antineoplastic Agents↗
PubMed1984

Chemotherapeutic susceptibility of human bone marrow progenitor cells and human myelogenous leukemia cells (HL-60) in co-culture: preliminary report.

We determined the chemotherapeutic susceptibility of normal human granulocyte progenitor cells (CFU-C) and acute myelogenous leukemia cells (HL-60) in co-culture. Nucleated bone marrow cells and HL-60 cells were mixed in 0.3% agar containing McCoy's 5A medium, fetal bovine serum, human placenta-conditioned medium, and various concentrations of chemotherapeutic agents. They were incubated in 5% humidified CO2 at 37 degrees C for 8-10 days. CFU-C and HL-60 colonies were differentiated morphologically. The formation of CFU-C was progressively inhibited with the increasing number of HL-60 cells, whereas the presence or absence of bone marrow cells did not influence the number of HL-60 colonies. In separate culture, HL-60 cells were more sensitive to vincristine than were CFU-C cells. In co-culture, however, the CFU-C became more sensitive to vincristine than in the separate culture. Similarly, co-culture CFU-C were more sensitive to daunorubicin than in separate culture. These data indicate that HL-60 leukemic cells exert inhibitory effects on normal bone marrow CFU-C; in such an inhibited state, normal bone marrow is more susceptible to certain chemotherapeutic agents.

Bone Marrow↗
PubMed1984

[Differential cell growth inhibition and terminal differentiation induction by chemotherapeutic agents of a human acute myelogenous leukemia cell line (HL-60) in vitro].

The relationship between cell growth inhibitory effects and terminal differentiation-inducing effects of nine clinically active chemotherapeutic agents was evaluated using HL-60, a human acute myelogenous leukemia cell line. Continuous exposure to HL-60 cells of adriamycin, daunorubicin, mitoxantrone, m-AMSA, cytosine arabinoside, 6-thioguanine (6-TG), actinomycin-D (Act-D) and vincristine resulted in percentage increase of morphologically differentiated cells and phagocytic cells. Hydrocortisone at a concentration of up to 10(-4) M failed to produce this effect. Examination of actual numbers per flask of morphologically differentiated cells and phagocytic cells revealed, however, that all these agents except Act-D and 6-TG failed to produce a numerical increase in differentiated cells in comparison with those of control groups at day 6. Only Act-D and 6-TG were able to produce increases in the percentage, as well as actual number, of differentiated cells. These data indicate that the percentage increase in terminal differentiation-induced cells by certain chemotherapeutic agents is due not to their ability to increase differentiated cells but to their ability to inhibit the growth of primitive cells preferentially.

Anthraquinones↗
PubMed1983

[Drug sensitivity of human acute myelocytic leukemia cells (HL-60) and normal human myelocytes (CFU-C) in a co-culture].

The chemotherapeutic susceptibility of normal human granulocyte-macrophage progenitor cells (CFU-C) and established human acute myelogenous leukemia (AML) cells (HL-60) in co-culture were determined. Nucleated marrow cells (2 X 10(5)) and HL-60 cells (5 X 10(3)) were mixed in 0.33% agar containing McCoy's 5a medium, 10% fetal calf serum, 0.1 ml of human placenta-conditioned medium and various concentrations of vincristine, cytosine arabinoside or daunorubicin to a total of 1.1 ml. They were incubated in 5% humidified CO2 at 37 degrees C for 8 to 10 days. CFU-C and HL-60 colonies were differentiated morphologically. In the absence of chemotherapeutic agents, the CFU-C colony formation was inhibited with the increasing number of HL-60 cells. CFU-C is equivalent or less sensitive than the leukemic cells in separate culture, but in co-culture it becomes more susceptible to vincristine and daunorubicin. These data indicate AML cells exert inhibitory effects on normal marrow CFU-C. In such state, normal hematopoietic cells become more susceptible to certain chemotherapeutic agents.

Adult↗
PubMed1979

Serum Zn content in tumor-bearing rats treated with anticancer drugs.

The serum Zn content in rats bearing Yoshida-Sarcoma, AH 66F, AH 13 or AH 109A was found to be low as compared with that in normal controls. In the rats which had received intraperitoneal inoculum of Yoshida-Sarcoma, the effects of anticancer drugs were closely related to the changes in serum Zn content. Namely, serum Zn content increased and approached the normal range almost parallel with the prolongation of survival time by anticancer drugs. As the causes responsible for the reduction in quantity of serum Zn in the tumor-bearing rats, the reduction of serum albumin content and the accumulation of Zn in the tumor tissue and organs such as the liver and kidneys were suggested.

Animals↗
PubMed1977

Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.

Clinical effect of 5-fluorouracil or chromomycin-A3 alone, 5-fluorouracil + chromomycin-A3, and of the first two plus prednisolone on gastrointestinal and other solid tumors was evaluated. Out of 133 cases acceptable for evaluation, the number of responders was as follows: 3 (18.8%) of 6 cases treated with 5-fluorouracil alone, 1 (9.1%) of 11 cases treated with chromomycin-A3 or chromomycin-A3 hemisuccinate, 13 (21.7%) of 60 cases on the two-drug regimen, and 21 (45.7%) of 46 cases on the three-drug regimen. In cases of stomach carcinoma, response rate to the three-drug regimen was 54.2% (13/24), significantly higher than that of other regimens. At least 25% regression in the size of primary tumor was observed in 2 (7.1%) of 28 cases on the two-drug regimen and in 6 (33.3%) of 18 cases on the three-drug regimen. Of 51 cases on the three-drug regimen, steroid diabetes developed in 5 cases, moon face in 4 cases, and gastric ulcer in 1 case. However, toxic effect of these regimens (especially appearance of leucopenia) was less than those of previously tried combined regimens. The duration of response, on an average, was 10.8 weeks in 13 cases on the two-drug regimen and 11.7 weeks in 21 cases on the three-drug regimen. It was concluded from these results that a better response is obtained by the three-drug regimen than other regimens, and that prednisolone in combination, in addition to its favorable effect in improving the general condition of the patients, might enhance the anticancer effect of the drugs used in combination.

Adenocarcinoma↗